COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PXPX BHBH FPVFPV FLVFLV PVP-IPI CICI BLBL RDRD
Ivermectin study #75 of 86
3/11 Meta
Bryant et al., Research Square, doi:10.21203/ (OSF preprints 3/11) (Preprint)
Ivermectin for prevention and treatment of COVID-19 infection: a systematic review and meta-analysis
Source   PDF   Share   Tweet
Systematic review and meta analysis of 21 RCTs finding mortality RR 0.32 [0.14-0.72], and prophylaxis case RR 0.14 [0.09-0.21].

Bryant et al., 3/11/2021, preprint, 7 authors.
risk of death, 68.0% lower, RR 0.32, p = 0.006.
risk of COVID-19 case, 86.0% lower, RR 0.14, p < 0.001.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 86 studies    Meta analysis
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation.